Splenomegaly Therapeutics Market, Global Outlook and Forecast 2022-2028

March 2022 | 62 pages | ID: S898CCD33355EN
Market Monitor Global

Abstracts

Splenomegaly is an enlargement of the spleen.The spleen usually lies in the left upper quadrant (LUQ) of the human abdomen. Splenomegaly is one of the four cardinal signs of hypersplenism which include: some reduction in number of circulating blood cells affecting granulocytes, erythrocytes or platelets in any combination; a compensatory proliferative response in the bone marrow; and the potential for correction of these abnormalities by splenectomy.

This report contains market size and forecasts of Splenomegaly Therapeutics in Global, including the following market information:

Global Splenomegaly Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Splenomegaly Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Drug Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Splenomegaly Therapeutics include GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Novartis AG and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Splenomegaly Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Splenomegaly Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Splenomegaly Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Drug Therapy
• Vaccination
• Others

Global Splenomegaly Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Splenomegaly Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Normal (Not Splenomegaly)
• Moderate Splenomegaly
• Severe Splenomegaly

Global Splenomegaly Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Splenomegaly Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Splenomegaly Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Splenomegaly Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• GlaxoSmithKline plc
• Incyte Corporation
• Merck & Co., Inc.
• Novartis AG
• Sanofi

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Splenomegaly Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Splenomegaly Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL SPLENOMEGALY THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Splenomegaly Therapeutics Market Size: 2021 VS 2028
2.2 Global Splenomegaly Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Splenomegaly Therapeutics Players in Global Market
3.2 Top Global Splenomegaly Therapeutics Companies Ranked by Revenue
3.3 Global Splenomegaly Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Splenomegaly Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Splenomegaly Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Splenomegaly Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Splenomegaly Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Splenomegaly Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Splenomegaly Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Drug Therapy
  4.1.3 Vaccination
  4.1.4 Others
4.2 By Type - Global Splenomegaly Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Splenomegaly Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Splenomegaly Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Splenomegaly Therapeutics Market Size, 2021 & 2028
  5.1.2 Normal (Not Splenomegaly)
  5.1.3 Moderate Splenomegaly
  5.1.4 Severe Splenomegaly
5.2 By Application - Global Splenomegaly Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Splenomegaly Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Splenomegaly Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Splenomegaly Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Splenomegaly Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Splenomegaly Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Splenomegaly Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Splenomegaly Therapeutics Revenue, 2017-2028
  6.3.2 US Splenomegaly Therapeutics Market Size, 2017-2028
  6.3.3 Canada Splenomegaly Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Splenomegaly Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Splenomegaly Therapeutics Revenue, 2017-2028
  6.4.2 Germany Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.3 France Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.5 Italy Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.6 Russia Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Splenomegaly Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Splenomegaly Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Splenomegaly Therapeutics Revenue, 2017-2028
  6.5.2 China Splenomegaly Therapeutics Market Size, 2017-2028
  6.5.3 Japan Splenomegaly Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Splenomegaly Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Splenomegaly Therapeutics Market Size, 2017-2028
  6.5.6 India Splenomegaly Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Splenomegaly Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Splenomegaly Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Splenomegaly Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Splenomegaly Therapeutics Market Size, 2017-2028
  6.7.3 Israel Splenomegaly Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Splenomegaly Therapeutics Market Size, 2017-2028
  6.7.5 UAE Splenomegaly Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 GlaxoSmithKline plc
  7.1.1 GlaxoSmithKline plc Corporate Summary
  7.1.2 GlaxoSmithKline plc Business Overview
  7.1.3 GlaxoSmithKline plc Splenomegaly Therapeutics Major Product Offerings
  7.1.4 GlaxoSmithKline plc Splenomegaly Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 GlaxoSmithKline plc Key News
7.2 Incyte Corporation
  7.2.1 Incyte Corporation Corporate Summary
  7.2.2 Incyte Corporation Business Overview
  7.2.3 Incyte Corporation Splenomegaly Therapeutics Major Product Offerings
  7.2.4 Incyte Corporation Splenomegaly Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Incyte Corporation Key News
7.3 Merck & Co., Inc.
  7.3.1 Merck & Co., Inc. Corporate Summary
  7.3.2 Merck & Co., Inc. Business Overview
  7.3.3 Merck & Co., Inc. Splenomegaly Therapeutics Major Product Offerings
  7.3.4 Merck & Co., Inc. Splenomegaly Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Merck & Co., Inc. Key News
7.4 Novartis AG
  7.4.1 Novartis AG Corporate Summary
  7.4.2 Novartis AG Business Overview
  7.4.3 Novartis AG Splenomegaly Therapeutics Major Product Offerings
  7.4.4 Novartis AG Splenomegaly Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Novartis AG Key News
7.5 Sanofi
  7.5.1 Sanofi Corporate Summary
  7.5.2 Sanofi Business Overview
  7.5.3 Sanofi Splenomegaly Therapeutics Major Product Offerings
  7.5.4 Sanofi Splenomegaly Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Sanofi Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Splenomegaly Therapeutics Market Opportunities & Trends in Global Market
Table 2. Splenomegaly Therapeutics Market Drivers in Global Market
Table 3. Splenomegaly Therapeutics Market Restraints in Global Market
Table 4. Key Players of Splenomegaly Therapeutics in Global Market
Table 5. Top Splenomegaly Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Splenomegaly Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Splenomegaly Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Splenomegaly Therapeutics Product Type
Table 9. List of Global Tier 1 Splenomegaly Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Splenomegaly Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Splenomegaly Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Splenomegaly Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Splenomegaly Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Splenomegaly Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Splenomegaly Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Splenomegaly Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Splenomegaly Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. GlaxoSmithKline plc Corporate Summary
Table 31. GlaxoSmithKline plc Splenomegaly Therapeutics Product Offerings
Table 32. GlaxoSmithKline plc Splenomegaly Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Incyte Corporation Corporate Summary
Table 34. Incyte Corporation Splenomegaly Therapeutics Product Offerings
Table 35. Incyte Corporation Splenomegaly Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Merck & Co., Inc. Corporate Summary
Table 37. Merck & Co., Inc. Splenomegaly Therapeutics Product Offerings
Table 38. Merck & Co., Inc. Splenomegaly Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Novartis AG Corporate Summary
Table 40. Novartis AG Splenomegaly Therapeutics Product Offerings
Table 41. Novartis AG Splenomegaly Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Sanofi Corporate Summary
Table 43. Sanofi Splenomegaly Therapeutics Product Offerings
Table 44. Sanofi Splenomegaly Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Splenomegaly Therapeutics Segment by Type in 2021
Figure 2. Splenomegaly Therapeutics Segment by Application in 2021
Figure 3. Global Splenomegaly Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Splenomegaly Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Splenomegaly Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Splenomegaly Therapeutics Revenue in 2021
Figure 8. By Type - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Splenomegaly Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Splenomegaly Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. GlaxoSmithKline plc Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Incyte Corporation Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck & Co., Inc. Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis AG Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Sanofi Splenomegaly Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)